Nasdaq · Biotech stocks database
GRFS — Grifols S.A.
GRFS (Grifols S.A.) stock: $7.39, $5.08B market cap, $969.4M cash, $4.49B EV, $5.08B fully diluted market cap. Next expected readout: Sep-27. Lead program: Alpha-1 15% (Alpha 1 Antitrypsin Deficiency), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$4,492.4M
Balance sheet
Cash $969.4M Debt $380.8M Net cash $588.6M Enterprise value $4,492.4M Basic shares 687.1M shares Fully diluted shares 687.6M shares Fully diluted market cap $5,081.0M Cash per share $1.41
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history Loading GRFS daily closes…
Loading price history…
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Now - Oct 24, 2026 Alpha-1 MP Phase 3 Pulmonary Emphysema in Alpha-1 PI Deficiency — Jan 12 - Feb 23 Albumin infusion (25% albumin) Phase 2 Cirrhosis; Ascites Hepatic — Nov 11 - Dec 23 Alpha-1 15% Phase 3 Alpha 1 Antitrypsin Deficiency — Feb 11 - Mar 24 Gamunex-C Phase 3 CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) — Oct 12 - Nov 23 Gamunex-C, 10% Injectable Solution Phase 3 Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphom — Oct 13 - Nov 24 Alpha-1 MP Phase 3 Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency — Jan 12 - Feb 23 Plasma-derived AT-III concentrate Phase 3 Antithrombin III Deficiency — Sep 12 - Oct 24 Xembify Phase 3 Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
Pipeline Lead drug Alpha-1 15% Lead indication Alpha 1 Antitrypsin Deficiency Lead phase Phase 3 Active trials 8 Collaborator trials 5
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07555483 Phase 3 Recruiting Sponsor GRFS — Alpha 1 Antitrypsin Deficiency — NCT07540221 Phase 3 Recruiting Sponsor GRFS — CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) — NCT07582432 Phase 3 Recruiting Sponsor GRFS — Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphom — NCT02796937 Phase 3 Enrolling by invitation Sponsor GRFS — Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency — NCT00319228 Phase 3 Active, not recruiting Sponsor GRFS — Antithrombin III Deficiency — NCT05645107 Phase 3 Recruiting Sponsor GRFS — Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia — NCT01983241 Phase 3 Active, not recruiting Sponsor GRFS — Pulmonary Emphysema in Alpha-1 PI Deficiency — NCT00555555 Not disclosed Active, not recruiting Sponsor GRFS — Von Willebrand Disease — NCT06052176 Phase 2 Active, not recruiting Collaborator Hunter Holmes Mcguire Veteran Affairs Medical Center — Cirrhosis; Hepatic Encephalopathy — NCT05794165 Phase 2 Enrolling by invitation Collaborator Bryan Cotton — Trauma Injury; Thromboembolism; Venous Thromboembolism — NCT06812390 Phase 2 Recruiting Collaborator Anahita Rabiee MD MHS — Cirrhosis; Ascites Hepatic — NCT07152834 Not disclosed Recruiting Collaborator Muğla Sıtkı Koçman University — Alpha 1-antitrypsin Deficiency (AATD) —
Sponsor-matched active trials from ClinicalTrials.gov (8 as sponsor, 5 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 13 active trials for Grifols Therapeutics LLC on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.